Risperidone and severe cerivastatin-induced rhabdomyolysis [2]

Journal of Internal Medicine

Volumn 251, Issue 2, 2002, Pages 177-178

  Giner, V ^a   Munoz R ^a   Redon J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CERIVASTATIN; CYTOCHROME P450 2D6; DEBRISOQUINE; GEMFIBROZIL; LORAZEPAM; LORMETAZEPAM; NIFEDIPINE; PRAVASTATIN; RISPERIDONE; SPARTEINE;

AGED; ASPIRATION BIOPSY; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; DISEASE SEVERITY; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ASSAY; ENZYME POLYMORPHISM; FEMALE; HUMAN; LABORATORY TEST; LETTER; LIVER EXAMINATION; LIVER METABOLISM; MENTAL DISEASE; PAIN; PRIORITY JOURNAL; RHABDOMYOLYSIS; TOXIC HEPATITIS; VIRUS DETECTION; WALKING;

AGED; ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRIDINES; RHABDOMYOLYSIS; RISK FACTORS; RISPERIDONE;

EID: 0036172252     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00936.x     Document Type: Letter

References (7)

1. Drug treatment of lipid disorders
2. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism. Monograph for physicians
3. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
4. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
5. Acute rhabdomyolysis associated with cerivastatin therapy
6. Cerivastatin-induced rhabdomyolisis
7. Rapid onset of risperidone-induced hepatotoxicity